AADI BIOSCIENCE INC AADI 深 沪
已收盘 03-18 16:00:00 美东时间
2.05
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 2.05
- 总市值 4293.11万
- 52周最高 3.812
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.21
- 委 比 0.00%
- 总股本 2094.20万
- 历史最高 65.25
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.10
- 每 手 1
- 风险率 0.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Piper Sandler Downgrades Aadi Bioscience to Neutral, Lowers Price Target to $1.75
Piper Sandler analyst Joseph Catanzaro downgrades Aadi Bioscience (NASDAQ:AADI) from Overweight to Neutral and lowers the price target from $5 to $1.75.
2024-08-27 22:46
--Piper Sandler Downgrades Aadi Bioscience to Neutral From Overweight
05:16 AM EDT, 08/27/2024 (MT Newswires) -- Price: 1.7205, Change: -0.03, Percent Change: -1.69
2024-08-27 17:16
Cancer Focused-Aadi Bioscience Stock Plunges As Solid Tumor Trial Falls Short Of Expectations
Tuesday, Aadi Bioscience Inc. (NASDAQ:AADI) announced it will halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlik...
2024-08-21 21:07
Traders Await Fed Minutes as US Equity Futures Post Narrow Gains Pre-Bell
08:51 AM EDT, 08/21/2024 (MT Newswires) -- US equity futures were cautiously higher before Wednesday's opening bell as traders looked ahead to minutes from the last Federal Reserve meeting for clues about future monetary policy. The Dow Jones Industrial Average futures gained 0.2%, S&P 500 futures i...
2024-08-21 20:51
HC Wainwright & Co. Reiterates Neutral on Aadi Bioscience
HC Wainwright & Co. analyst Robert Burns reiterates Aadi Bioscience (NASDAQ:AADI) with a Neutral.
2024-08-21 20:27
--TD Cowen Downgrades Aadi Bioscience to Hold From Buy
06:25 AM EDT, 08/21/2024 (MT Newswires) -- Price: 1.1800, Change: -0.44, Percent Change: -27.16
2024-08-21 18:25
Why Keysight Technologies Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Shares of Keysight Technologies, Inc. (NYSE:KEYS) rose sharply in today's pre-market trading after the company reported stronger-than-expected results for its third quarter. The company said it sees fourth-quarter earnings between $1.53 and $1.59 per share, versus the $1.54 estimate, and revenue in ...
2024-08-21 17:47
Aadi Bioscience Shares Fall as Tumor Treatment Trial Halted; Job Cuts Planned
05:59 PM EDT, 08/20/2024 (MT Newswires) -- Aadi Bioscience (AADI) shares fell 27% in after-hours trading Tuesday after the company said its Precision1 trial of nab-sirolimus in cancer patients is unlikely to meet the efficacy threshold for regulatory approval. The company said it decided to halt the...
2024-08-21 05:59
Aadi Bioscience Says PRECISION1 Tumor-agnostic Trial Unlikely To Meet Regulatory Threshold To Support Accelerated Approval And Will Be Halted
An analysis by the Independent Data Monitoring Committee demonstrated that the study was unlikely to exceed an efficacy threshold necessary to support an accelerated approval, the key goal of this Phase 2 study. The approximately 25 patients in PRECISION1 who are still benefiting from nab-sirolimus...
2024-08-21 05:03
